Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple text message transform cancer care?

NCT ID NCT07745816

Symptom relief Sponsor: National Cancer Centre, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and manage them. The goal is to improve quality of life and reduce hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A behavioral intervention: regular SMS text reminders to complete an online symptom questionnaire, with follow-up phone calls from a palliative care coordinator if symptoms are flagged.
What this could lead to
If effective, this approach could help advanced cancer patients receive earlier palliative care, improving quality of life and reducing hospital admissions.
What could go wrong
This is a relatively small trial, and the intervention depends on patient engagement with text messages and phone calls. It may not work for everyone or in all healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion criteria for patients: 1. 21 years old or older 2. Diagnosed of advanced cancer diagnosis, defined as metastatic or recurrent/ progressive Stage III/IV solid tumour 3. Has an unplanned hospital admission and expected to be discharged home 4. Able to speak English or Mandarin Chinese or Malay 5. Able to provide informed consent Additional inclusion criteria for patient participants of semi-structured interviews are: 6. Enrolled in the SPARKLE-2 RCT, whether randomized to the SPARKLE intervention or usual care group and regardless of fidelity to trial procedures. * Inclusion criteria for caregivers: 1. 21 years old or older 2. Self-endorsing or identified by an enrolled patient as a spouse/partner, relative or friend who knows them well and who provides support due to their cancer 3. Able to speak English or Mandarin Chinese or Malay 4. Able to provide informed consent * Inclusion criteria for healthcare providers: 1. 21 years old or older 2. Healthcare professional who is involved in the clinical care of patients with advanced cancer for at least 50% of their work hours 3. Able to provide informed consent 4. Involved in the processes of the SPARKLE-2 Exclusion Criteria: * Exclusion criteria for patients: 1. Assessed by the treating physician as unable to complete study procedures 2. Unable to complete patient-reported outcome measures * Exclusion criteria for caregivers: 1\. Unable to complete interviews * Exclusion criteria for healthcare providers: 1. Healthcare professionals that are not providing care for cancer patients. 2. Unable to complete interviews

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoplasms Palliative care

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Cancer Centre, Singapore

    Singapore, 168583, Singapore

  • Singapore General Hospital

    Singapore, 169608, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.